Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'

Affiliations

¹ Neurophenomenology of Consciousness Lab, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zürich, Switzerland.
² Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zürich, Switzerland.
³ Division Neuropsychology, Department of Psychology, University of Zürich, Zürich, Switzerland.

Published Erratum

Robin von Rotz et al. EClinicalMedicine. 2023.

. 2023 Jan 30:56:101841.

doi: 10.1016/j.eclinm.2023.101841. eCollection 2023 Feb.

¹ Neurophenomenology of Consciousness Lab, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zürich, Switzerland.
² Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zürich, Switzerland.
³ Division Neuropsychology, Department of Psychology, University of Zürich, Zürich, Switzerland.

Abstract

[This corrects the article DOI: 10.1016/j.eclinm.2022.101809.].

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.
von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, Seifritz E, Nowak A, Nowak P, Jäncke L, Preller KH, Vollenweider FX. von Rotz R, et al. EClinicalMedicine. 2022 Dec 28;56:101809. doi: 10.1016/j.eclinm.2022.101809. eCollection 2023 Feb. EClinicalMedicine. 2022. PMID: 36636296 Free PMC article.